Zairen Sun, Ph.D.
Zairen has over 20 years of experience in the biotechnology industry. He founded Vigene Biosciences in 2012 with the focus of aiding research to cure human diseases through gene therapy and cell therapy. Prior to founding Vigene Biosciences, Zairen was the head of R&D at OriGene Technologies Inc. During his 14-year tenure at OriGene, Zairen and his team created the most comprehensive collection of human full-length cDNA clones and their derivative products like proteins and antibodies. Zairen has many patents and publications. He holds a Ph.D. degree in molecular biology from the University of Maryland at College Park.
Jeffrey Hung, Ph.D.
Jeffrey has over 20 years of experience in the biotechnology industry. He joined Vigene in 2016 and orchestrated the acquisition of Omnia Biologics. He has also overseen Vigene’s expansion into GMP manufacturing and new product areas such as biosensors. An experienced entrepreneur, Jeffrey was instrumental in successfully growing GenScript and SABiosciences, two previous companies, to IPO and acquisition stage, respectively. He also previously held the position of Chief Marketing Officer at ATCC. Jeffrey is the author of multiple patents, publications, and book chapters. He holds a Ph.D. in genetics from Cornell University, an MBA from UC Berkeley, and a B.S. in biology from Peking University.
Ms. Molly S. McGlaughlin
Ms. McGlaughlin, a long term Biologics Contract Development and Manufacturing Organization (CDMO) industry senior executive, comes to us with 27 years of experiences in biologics manufacturing and development. She has served on the executive management teams of BioLexis, BioVectra, EirGenix, Selexis S.A., Natrix Separations, Cytovance Biologics, Avecia Biotechnology (now Fuji Diosynth), and Patheon. Ms. McGlaughlin is also a Colonel in the US ARMY Reserves with experience as a Joint Information Warfare Planner and commanding at the Brigade level. Ms. McGlaughlin earned her BS from Norwich University and master’s degrees from Capella University (ABD), US ARMY War College, and University of Massachusetts Boston.
Audrey Chang, Ph.D.
Dr. Chang is a world leader in biologics QC and analytical testing; and has been leading the QC development efforts for BioReliance/MilliporeSigma for cell gene therapy, biologics and other modalities of pharmaceutical testing for over 20 years. Dr. Chang is the author of more than 15 papers and has served as a keynote speaker for many conferences and meetings. Dr. Chang earned her Ph.D in Biology from John Hopkins University and B.S. from University of Maryland (College Park).
Patrick has over 25 years of experience in the pharmaceutical/biotech industry and has held positions in Research & Development, Quality Control/Quality Assurance and for the last 17+ years in Business Development, all of which have been in the Contract Development and Manufacturing space.
Patrick joined Vigene in 2020 as Vice President of Business Development. Prior to joining Vigene, Patrick held Senior Business Development positions at Emergent BioSolutions, Catalent/Aptuit and Azopharma. Patrick earned his Bachelor of Science from Fredonia State University (ACS accredited) and a Master of Science in Analytical Chemistry (LC/MS) from Clemson University.
Chris joined Vigene in 2019 as Vice President of GMP Manufacturing and leads the development, technical transfer, manufacturing, and facility teams. Chris started his career in the late 1980’s in the chemical process industry at DuPont where he developed an early commitment to safety and continuous improvement. When he transitioned into biologics in 1994, Chris spent the next 10-15 years of his biologics career pioneering the use of quality-by-design and continuous improvement concepts in the biopharm industry. In addition to his foundation in continuous improvement, Chris has a broad and integrated experience in R&D, cGMP manufacturing, and commercial technical support. Those roles span a wide range of molecules including monoclonal antibodies (MAbs), fusion proteins, live-attenuated and recombinant viral vaccines, and gene therapy viral vectors from pre-clinical development through Phase III clinical manufacturing. Chris holds a B.S. in chemical engineering from the University of Massachusetts, Amherst.